Regulation of sarco(endo)plasmic reticulum Ca2+ adenosine triphosphatase by phospholamban and sarcolipin: implication for cardiac hypertrophy and failure.

Abstract	The cardiac isoform of sarco(endo)plasmic reticulum Ca(2)(+) adenosine triphosphatase (SERCA2a) plays an important role in the contraction and relaxation of cardiac muscle. Phospholamban (PLN) and its homologue sarcolipin (SLN) are the endogenous regulators of SERCA2a. Evidence is accumulating that SERCA2a is intimately involved in the pathogenesis of cardiac hypertrophy and failure. Recent studies using genetically engineered animals revealed the implication of PLN for the development of cardiomyopathic phenotypes. This review focuses on advances in the understanding of molecular regulation of SERCA2a by PLN and SLN, and their implications for cardiac hypertrophy and failure in vivo.
Authors	Michio Asahi, Hiroyuki Nakayama, Michihiko Tada, Kinya Otsu
Journal	Trends in cardiovascular medicine (Trends Cardiovasc Med) Vol. 13 Issue 4 Pg. 152-7 (May 2003) ISSN: 1050-1738 [Print] United States
PMID	12732449 (Publication Type: Journal Article, Review)
Chemical References	Calcium-Binding Proteins Muscle Proteins Proteolipids phospholamban sarcolipin Calcium-Transporting ATPases
Topics	Animals Calcium-Binding Proteins (pharmacology, physiology) Calcium-Transporting ATPases (physiology) Cardiomegaly (enzymology, physiopathology) Heart Failure (enzymology, physiopathology) Humans Muscle Proteins (pharmacology, physiology) Myocardial Contraction (physiology) Proteolipids (pharmacology, physiology) Sarcoplasmic Reticulum (enzymology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!